Journal of Asthma and Allergy最新文献

{"title":"Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study.","authors":"Muhammad Adrish, Jessica K DeMartino, Donna Carstens, Mandy Jackson, Jill Schinkel, Kathleen Wilson, Joseph Tkacz","doi":"10.2147/JAA.S568990","DOIUrl":"10.2147/JAA.S568990","url":null,"abstract":"<p><strong>Purpose: </strong>Clinical trials have demonstrated benralizumab reduces exacerbations among patients with severe asthma. Evidence on the effectiveness of benralizumab among older adults is limited. The objective was to assess the change in the annual asthma exacerbation rate (AAER), exacerbation-related medical costs, and asthma medication utilization 12 months before and after the initiation of benralizumab in Medicare patients, as well as in an all-payer sample, in a subgroup with prior biologic use, and segmented by benralizumab adherence status.</p><p><strong>Methods: </strong>This was a single-arm, 12-month pre-/post-, within-subjects study using 2017-2023 MORE² Registry^® and Medicare Fee-For-Service databases. Included patients met the following criteria: 1) prescription for benralizumab (index date) and ≥1 refill within 90 days, 2) 12 months of database enrollment preceding and following the index date, 3) ≥1 inpatient or ≥2 outpatient claims with a diagnosis of asthma during the baseline period, and 4) ≥2 asthma exacerbations during the baseline period. Outcomes included percent change in AAER, exacerbation-related medical costs, and asthma medication utilization.</p><p><strong>Results: </strong>The study included 4,611 Medicare patients and 7,706 patients in the all-payer sample. Among Medicare patients, there was a 43.5% reduction in AAER (mean [SD], 3.8[2.0] to 2.2[2.2] exacerbations per year; <i>P</i> <0.001). Exacerbation-related medical costs decreased across all cost categories, as did use of corticosteroids and other asthma medications. Reductions in outcomes were also observed in an all-payer sample.</p><p><strong>Conclusion: </strong>Medicare patients with severe asthma initiating benralizumab demonstrated meaningful reductions in AAER, exacerbation-related medical costs, and corticosteroid use in a real-world setting.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"568990"},"PeriodicalIF":3.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13033255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147581248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sensitization to Dog Dander Allergen Can f 1 is Associated with Asthma Symptom Severity and Exacerbations in a Singapore-Malaysia Cohort.","authors":"Yang Yie Sio, Tan Ching Ong, Yee-How Say, Kavita Reginald, Fook Tim Chew","doi":"10.2147/JAA.S581910","DOIUrl":"10.2147/JAA.S581910","url":null,"abstract":"<p><strong>Background: </strong>Sensitization to pet dander allergens has been increasing globally, however, its clinical relevance to allergic disease exacerbation remains underexplored.</p><p><strong>Objective: </strong>We aimed to determine the prevalence of serum-specific IgE (SSIgE) response to the major dog allergen <i>Canis familiaris</i> 1 (Can f 1), and to evaluate its association with asthma-related symptom severity and exacerbation in a Singapore/Malaysia population.</p><p><strong>Patients and methods: </strong>A comprehensive serological profiling of specific IgE responses to 38 common inhalant and seafood allergen sources was performed in 736 young adults from the Singapore/Malaysia Cross-sequential Genetics and Epidemiology Study (SMCGES) sub-cohort. SSIgE levels were analyzed in relation to asthma diagnosis, symptom frequency, and exacerbation history.</p><p><strong>Results: </strong>Detectable Can f 1-specific IgE was present in 13.5% of participants, predominantly at low-grade Class 1-2 levels (0.35-3.49 IU/mL). Individuals with pre-existing sensitization to common inhalant and seafood allergen sources, including house dust mites (HDM), cat dander (<i>Felis domesticus</i> 1, Fel d 1), pollen, fungi, crustaceans, mollusks, and fish, showed a significantly higher rate of Can f 1-specific IgE response. Among asthmatic subjects, elevated Can f 1 SSIgE levels were significantly associated with recent (past 12 months) wheezing (<i>p</i>=0.005), daytime (<i>p</i>=0.019) and nighttime asthma attacks (<i>p</i>=0.033), and asthma exacerbations (<i>p</i>=0.001). These associations remained to be significant and consistent in trend among asthmatic patients sensitized to HDM allergen sources.</p><p><strong>Conclusion: </strong>Sensitization to Can f 1 is associated with increased asthma-related symptom burden and exacerbation risk, particularly in individuals with pre-existing atopy among young adults in Singapore and Malaysia. These findings highlight Can f 1-specific IgE as a potential molecular marker for identifying higher-risk asthma phenotypes in the tropical environment.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"581910"},"PeriodicalIF":3.0,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13025727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147573973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systems Biology and Multi-Omics in Asthma and COPD: A Systematic Review of Computational Approaches (2010-2024).","authors":"Mushabbab A Alahmari","doi":"10.2147/JAA.S575312","DOIUrl":"10.2147/JAA.S575312","url":null,"abstract":"<p><p>Systems biology approaches have contributed to advancing our understanding of complex respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). This systematic review evaluates the application of systems biology methodologies in respiratory medicine, focusing on multi-omics data integration and computational techniques for biomarker discovery and mechanistic understanding. Following PRISMA 2020 guidelines, we conducted a comprehensive literature search across Web of Science and Scopus databases, identifying 117 peer-reviewed documents published from 2010 to 2024. The review methodology employed bibliometric analysis combined with qualitative synthesis of included studies. Results demonstrate steady growth in systems biology applications for asthma and COPD research, with publication rates increasing by approximately 0.5 articles per year (<i>R²</i> = 0.73, p < 0.001). Bibliometric analysis identified five major research clusters: systems biology as a foundational methodological framework (Basic Theme), COPD-focused research as the most developed area (Motor Theme), gene expression analysis, disease classification approaches, and specialized lung disease investigations (Niche Theme). Multi-omics integration studies achieved 82-91% accuracy in disease classification tasks, with transcriptomics-based asthma endotyping validated in over 1500 patients across multiple cohorts. Network analysis approaches identified hub genes (IL-6, TNF-α, MMP9) replicated across three independent studies. Machine learning applications demonstrated 80-90% accuracy for diagnostic and prognostic tasks, though external validation remains limited, with only 15% of reviewed studies including independent validation cohorts. Significant challenges persist in data integration, computational reproducibility, and clinical translation. Most studies employed modest sample sizes (median n=89), and population diversity was limited, with 89% conducted in European-ancestry populations. This review provides a comprehensive assessment of systems biology progress in respiratory medicine, identifies methodological gaps, and highlights the need for standardized protocols, larger collaborative studies, and rigorous external validation to advance clinical implementation of systems biology findings in asthma and COPD management.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"575312"},"PeriodicalIF":3.0,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13007689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147512379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of Adult Severe Uncontrolled Asthma Patients in Primary Care and Modifications in Prescribed Inhalation Treatments.","authors":"Jon R Konradsen, Sylvia Packham, Lowie E G W Vanfleteren, Jörgen Syk, Apostolos Bossios, Caroline Stridsman","doi":"10.2147/JAA.S585933","DOIUrl":"10.2147/JAA.S585933","url":null,"abstract":"<p><strong>Background: </strong>Severe asthma outcomes in primary care are poorly documented. This study characterizes adults with severe uncontrolled asthma and evaluates modifications of prescribed inhalation therapy and exacerbations over 12 months.</p><p><strong>Methods: </strong>Adult primary care asthma patients, with visits recorded in the Swedish National Airway Register from July 2017 to February 2019 (index date), were included. Data were linked to National Prescribed Drug Register. Severe asthma was defined by adherence to high dose inhaled corticosteroids (ICS) ± long-acting beta-agonists (LABA) or ICS+LABA+long-acting muscarinic antagonists. Inhalation therapy was assessed 12 months pre- and post-index. All other variables were collected up to 24 months pre-index and 12 months post-index. Uncontrolled asthma was defined as Asthma Control Test ≤19.</p><p><strong>Results: </strong>Severe asthma was identified in 2789 patients, of which, 1261 had uncontrolled disease. Severe uncontrolled asthma associated with regular OCS use 24 months pre-index (OR 1.77, 95% CI 1.42-2.20), obesity (1.63, 1.32-2.02), primary school education (1.55, 1.22-1.96) and inversely associated with asthma management education (0.77, 0.66-0.90). Post-index, 5%, 55% and 45% increased, maintained or reduced their inhalation therapy, respectively. Patients increasing inhalation therapy had lower mean FEV₁% predicted (67.8 vs. 80.9 and 79.4), more regular OCS uses pre-index (34.8% vs. 17% and 21.9%), and high SABA use (33.3% vs. 27.3% and 21.3%). Post-index asthma exacerbations in severe uncontrolled asthma associated with rhinitis (1.46, 95% CI 1.14-1.88), cardiovascular disease (1.38, 1.06-1.80), high SABA use (1.79, 1.38-2.34), and treatment increase (1.83, 1.08-3.10).</p><p><strong>Conclusion: </strong>In primary care, severe uncontrolled asthma was among other factors associated with regular OCS use, obesity, lower educational level and absence of asthma management education. Uncontrolled patients already adhering to high dose ICS medication and further increased inhalation therapy were at greater risk of exacerbations, indicating the need for referral to secondary care.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"585933"},"PeriodicalIF":3.0,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13007693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147512447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salbutamol Reversal of Methacholine Induced Bronchoconstriction: Vibrating Mesh Nebulizer versus Pressurized Metered Dose Inhaler.","authors":"Beth E Davis, Brianne S Philipenko, Donald W Cockcroft","doi":"10.2147/JAA.S582087","DOIUrl":"10.2147/JAA.S582087","url":null,"abstract":"<p><strong>Background: </strong>Reversal of methacholine induced bronchoconstriction (MIB) is routinely achieved by administering 200 mcg salbutamol via pressurized metered dose inhaler (pMDI). The propellant in the inhaler (hydrofluoroalkane-134a) contributes to greenhouse gas emissions, negatively impacting the environment. One alternative to delivering bronchodilator would be using the Aerogen^® Solo vibrating mesh nebulizer (VMN). Using the VMN to deliver methacholine during MCT as well as bronchodilator after MCT could reduce the carbon footprint of testing by eliminating pMDI inhaler use. The current study compared bronchodilator reversal of MIB via pMDI to that of VMN.</p><p><strong>Methods: </strong>Sixteen individuals exhibiting airway hyperresponsiveness to methacholine completed a double blind, double dummy, placebo controlled, randomized, three-way crossover study. At each visit, participants underwent MCT followed by administration of placebo or salbutamol (200 mcg) via pMDI or VMN. Lung function and heart rate measurements were captured before and at 5, 10, 15, 30, 45 and 60 minutes after treatment administration.</p><p><strong>Results: </strong>Pre MCT FEV₁ did not differ between the three treatment arms (RM ANOVA p = 0.741). When corrected for repeated measures, the reduction in FEV₁ after MCT (30.5%, 27.4% and 24.8% for placebo, pMDI and VMN, respectively) was similar across groups. Mean FEV₁ values after administration of salbutamol via pMDI or VMN were significantly greater than after placebo at all timepoints (RM ANOVA p < 0.001) with no significant difference between methods of salbutamol administration. Mean heartrate did not differ between treatments before or after treatment.</p><p><strong>Conclusion: </strong>Use of the VMN for delivering salbutamol to reverse MIB is feasible. Doing so adds functionality to the use of this nebulizer for performing methacholine bronchoprovocation and reduces the negative environmental impact of pMDI inhalers.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"582087"},"PeriodicalIF":3.0,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13005985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to Biologic Therapies is Associated with Improved Clinical Outcomes and Reduced Healthcare Resource Utilization in Patients with Severe Asthma in Japan.","authors":"Hiroyuki Nagase, Urvee Karsanji, Hideaki Kunishige, Takeo Suzuki, Anna Vichiendilokkul, Liza Yuanita, Natsuki Sasakura, Jiaxuan Wang, Saeed Noibi","doi":"10.2147/JAA.S590261","DOIUrl":"https://doi.org/10.2147/JAA.S590261","url":null,"abstract":"<p><strong>Purpose: </strong>Biologic therapies have improved clinical outcomes and quality of life in patients with asthma, and treatment adherence is important for their effectiveness. This study evaluated 12-month adherence patterns for five asthma biologics approved in Japan and their impact on clinical and economic outcomes in patients with severe asthma.</p><p><strong>Methods: </strong>This non-interventional, cross-sectional, retrospective cohort study used Japan's Medical Data Vision database (June 2009-September 2024). Adults with severe asthma, ≥30 days of continuous enrollment pre-biologic initiation and ≥12 months of follow-up were included. Adherence was assessed using medication possession ratio (MPR). Group-based trajectory modeling (GBTM) characterized distinct adherence trajectories over time, providing insights into heterogeneous adherence behaviors and subgroup patterns. Impact of biologic adherence on exacerbations (defined by hospital admissions, emergency department visits or requiring oral/intravenous corticosteroids), healthcare resource utilization (HCRU) and pharmacy costs were analyzed descriptively.</p><p><strong>Results: </strong>Among 2904 eligible patients, average MPR was 62.6%-72.6% across the five biologics. Over 90% of patients received ≥1 follow-up dose of their biologic; with average MPR increased by 1%-6% among these patients versus the overall cohort. The GBTM analysis was conducted in 2531 patients without a biologic switch during follow-up, identifying seven distinct clusters with MPR ranging from 10.0% to 94.8%. Patients were also classified as adherent (41.1%), partially adherent (28.1%), minimally adherent (3.2%), or treatment discontinuation (27.6%), based on dosing frequency and intervals. Mean exacerbation rates defined by hospital admissions were low (0.02-0.08 events per patient/year). Exacerbations of any type typically increased with declining biologic adherence. Decreased adherence was generally associated with increased HCRU and higher asthma-related pharmacy costs, particularly when biologic costs were excluded.</p><p><strong>Conclusion: </strong>Biologic adherence was consistently associated with fewer exacerbations, reduced HCRU and lower asthma-related pharmacy costs (excluding biologic costs), reinforcing the importance of optimizing adherence in patients with asthma.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"590261"},"PeriodicalIF":3.0,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13005638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147498472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Designing an Incremental Egg Oral Immunotherapy Protocol: A Strategic Approach with Safety as a Priority.","authors":"Darin Munyuen, Araya Yuenyongviwat, Pasuree Sangsupawanich, Kokaew Chauikaew, Burat Srisuk, Tidawan Chanklay, Vanlaya Koosakulchai","doi":"10.2147/JAA.S591550","DOIUrl":"https://doi.org/10.2147/JAA.S591550","url":null,"abstract":"<p><strong>Purpose: </strong>Egg oral immunotherapy (OIT) has demonstrated clinical efficacy; however, 10-35% of patients discontinue treatment due to severe adverse reactions, particularly during the build-up phase. To improve safety, we developed an incremental egg OIT protocol with gradual dose escalation and an extended build-up period. This study aimed to evaluate the safety and efficacy of this protocol in children with egg allergy.</p><p><strong>Patients and methods: </strong>We retrospectively reviewed children aged 1-18 years with hen's egg allergy confirmed by oral food challenge (OFC) who initiated an incremental egg OIT protocol at Songklanagarind Hospital between August 2023 and March 2025. Demographic characteristics, serum specific immunoglobulin E (sIgE) levels to egg white, egg yolk, and ovomucoid, and adverse reactions during OIT were collected and analyzed.</p><p><strong>Results: </strong>Fourteen patients were included; four underwent egg yolk OIT (EY-OIT) and ten underwent egg white OIT (EW-OIT). The median age was 44.5 months (IQR 31-63) in the EY-OIT group and 29.5 months (IQR 22.5-65.25) in the EW-OIT group. Mild adverse reactions occurred in 6 of 14 patients (43%). Reported reactions included active eczema and itchy throat in the EY-OIT group, and perioral erythema, active eczema, and acute urticaria in the EW-OIT group. No severe adverse reactions were observed during the OIT build-up and maintenance phases. Thirteen patients (92.9%) successfully escalated doses according to the protocol, and nine patients reached the target maintenance dose.</p><p><strong>Conclusion: </strong>An incremental egg OIT protocol demonstrated a favorable safety profile in children with egg allergy. No severe adverse reactions occurred during the OIT build-up and maintenance phases, and most patients tolerated gradual dose escalation as planned, supporting the feasibility of this approach in real-world clinical practice.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"591550"},"PeriodicalIF":3.0,"publicationDate":"2026-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12998328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147486085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Immune Dysregulation in Allergic Rhinitis: Mechanisms, Comorbidities, and Implications for Targeted Therapy.","authors":"Danni Hui, Caizhen Shi, Yanpeng Fan, Mengjie Han, Yueyao Wang, Jundi Sun, Yajuan Xue, Erle Li","doi":"10.2147/JAA.S589195","DOIUrl":"https://doi.org/10.2147/JAA.S589195","url":null,"abstract":"<p><p>Allergic rhinitis (AR) has traditionally been regarded as a localized inflammatory disorder of the nasal mucosa. However, accumulating evidence indicates that AR is associated with systemic immune dysregulation characterized by peripheral eosinophilia, altered T helper cell polarization, circulating cytokine imbalances, and widespread inflammatory signaling. This systemic immune disturbance contributes to the frequent coexistence of AR with asthma, atopic dermatitis, and other immune-mediated conditions. These associations support the concept of AR as part of a unified airway and systemic allergic disease spectrum. In this review, we summarize current insights into the immunopathogenesis of AR from both local and systemic perspectives. We focus on epithelial barrier dysfunction, type 2 immune responses, and immune cell trafficking between the upper and lower airways. We further discuss emerging systemic inflammatory biomarkers and their potential clinical relevance in disease stratification and management. Finally, we highlight recent advances in allergen immunotherapy and targeted biologic therapies, emphasizing their implications for precision treatment of AR and its comorbidities. Recognizing AR as a manifestation of systemic immune dysregulation may facilitate improved disease classification and support the development of more effective, individualized therapeutic strategies.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"589195"},"PeriodicalIF":3.0,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12984071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147468096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Evaluation of Four Multiple Allergen Simultaneous Test (MAST) Systems in Clinical Practice.","authors":"Sojin Lee, Junhyup Song, Kyung-A Lee, Younhee Park","doi":"10.2147/JAA.S577413","DOIUrl":"https://doi.org/10.2147/JAA.S577413","url":null,"abstract":"<p><strong>Purpose: </strong>Multiple allergen simultaneous tests (MASTs) are widely used for screening allergen-specific immunoglobulin E owing to their convenience and cost-effectiveness. Recently, several automated MAST analyzers with expanded allergen panels have become available in Korea; however, comparative evaluations remain limited.</p><p><strong>Patients and methods: </strong>In this retrospective study, 200 residual serum samples from patients tested for suspected allergic diseases at a single tertiary hospital were analyzed. Each sample was tested using AdvanSure Alloscreen, AdvanSure Alloscreen Max108, SGTi-Allergy Screen, and PROTIA Allergy-Q. Semi-quantitative results (classes 0-6) were interpreted as positive at class ≥2. Concordance rates and Cohen's kappa coefficients were calculated.</p><p><strong>Results: </strong>Overall agreement between the MAST systems was high (91-93%), with Cohen's kappa values indicating substantial to almost perfect agreement (κ = 0.67-0.76). The agreement between AdvanSure Alloscreen and its upgraded version, AdvanSure AlloScreen Max108, was the highest. For common allergens in the Korean population, <i>Dermatophagoides pteronyssinus</i> and <i>Dermatophagoides farinae</i> showed moderate agreement (κ = 0.47-0.82, respectively) between the MAST systems. Re-testing of discrepant samples (n = 78; 31 allergens) using ImmunoCAP-often considered the gold standard for allergy testing-demonstrated the highest concordance for the SGTi Allergy Screen (76.39%).</p><p><strong>Conclusion: </strong>All four MAST systems demonstrated substantial to near-perfect qualitative agreement. The SGTi-Allergy Screen showed the best concordance with ImmunoCAP, whereas AdvanSure Alloscreen Max108 offered a balanced performance with broader allergen coverage. These findings indicate that laboratories should select a MAST system based on local needs, weighing analytical accuracy, allergen panel breadth, and overall testing efficiency.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"577413"},"PeriodicalIF":3.0,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12970036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147433109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Vitamin D Levels on Asthma Exacerbation in Asthmatic Patients in a Tertiary Hospital: Retrospective Study.","authors":"Alaa A Alhubaishi, Nora K Almutairi, Reem A Alghamdi, Maha A AlMolaiki, Nada A Alsaleh, Lina I Alnajjar, Sumaiah J Alarfaj, Hamdan Aljahdali","doi":"10.2147/JAA.S572118","DOIUrl":"https://doi.org/10.2147/JAA.S572118","url":null,"abstract":"<p><strong>Background: </strong>Asthma is a major global health issue, affecting over 260 million individuals and causing more than 450,000 deaths annually. A growing body of international and local research has investigated the link between Vitamin D levels and asthma outcomes. These studies suggest that Vitamin D may play a role in modulating immune responses, potentially influencing asthma control, the frequency of exacerbations, hospital visits, and overall disease severity. However, evidence remains contradictory, where other studies did not establish a direct link between vitamin D levels and asthma development given the limited real-world data from Saudi Arabia.</p><p><strong>Objective: </strong>This study aims to investigate the effect of serum Vitamin D levels and asthma exacerbations among adults, adolescents, and children within a Saudi population.</p><p><strong>Methods: </strong>A single-center retrospective cohort study was conducted at the National Guard Hospital in Riyadh, Saudi Arabia, involving 379 asthma patients with documented Vitamin D deficiency within the past 6 to 12 months. The primary outcome was the effect of serum Vitamin D levels and asthma exacerbations. The secondary outcome is defining the correlation between Vitamin D levels and asthma severity.</p><p><strong>Results: </strong>A significant difference in asthma exacerbation frequency was observed between the Vitamin D-deficient and adequate groups during both the 6- and 12-month periods, with the adequate group experiencing more frequent exacerbations (p = 0.030). Furthermore, significant associations were found between Vitamin D levels and emergency room visits (p < 0.001), as well as the need for rescue medication (p = 0.004).</p><p><strong>Conclusion: </strong>Interestingly, the results revealed that individuals with adequate vitamin D had a significantly higher frequency of exacerbations compared to those in the deficient group. These findings could be due to several confounding factors. Although vitamin D may contribute to overall respiratory health, its impact on severe asthma events may be overshadowed by other critical factors, such as Age and BMI, comorbidities, adherence to controller medications, and exposure to environmental triggers.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"19 ","pages":"572118"},"PeriodicalIF":3.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12956051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}